Trial reportBrain and behavior2019
Sanhuang Xiexin decoction promotes good functional outcome in acute ischemic stroke.
Trial report in Brain and behavior, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- Sanhuang Xiexin decoction promotes good functional outcome in acute ischemic stroke.Brain and behavior · 2019Trial
- The Role of Gut Microbiota-Derived Trimethylamine N-Oxide in the Pathogenesis and Treatment of Mild Cognitive Impairment.International journal of molecular sciences · 2025Review
- Heat syndrome types prediction of traditional Chinese medicine in acute ischemic stroke through deep learning: a pilot study.Frontiers in pharmacology · 2025Article
- Research progress in the relationship between gut microbiota metabolite trimethylamine N-oxide and ischemic stroke.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024Review
- Contribution of Trimethylamine N-Oxide (TMAO) to Chronic Inflammatory and Degenerative Diseases.Biomedicines · 2023Review
- Trimethylamine-N-oxide: a potential biomarker and therapeutic target in ischemic stroke.Frontiers in neurology · 2023Review
- Gut microbiota, a hidden protagonist of traditional Chinese medicine for acute ischemic stroke.Frontiers in pharmacology · 2023Review
- Integrated Traditional Chinese Medicine Improves Functional Outcome in Acute Ischemic Stroke: From Clinic to Mechanism Exploration With Gut Microbiota.Frontiers in cellular and infection microbiology · 2022Article
- Gut Microbiota-Related Effects of Tanhuo Decoction in Acute Ischemic Stroke.Oxidative medicine and cellular longevity · 2021Article
- Influence of Dietary Components and Traditional Chinese Medicine on Hypertension: A Potential Role for Gut Microbiota.Evidence-based complementary and alternative medicine : eCAM · 2021Review
- An ethnoveterinary study on medicinal plants used by the Buyi people in Southwest Guizhou, China.Journal of ethnobiology and ethnomedicine · 2020Article
- Modeling rapid and selective capture of nNOS-PSD-95 uncouplers from Sanhuang Xiexin decoction by novel molecularly imprinted polymers based on metal-organic frameworks.RSC advances · 2020Article
- Essential Role of Chinese Medicines in Mesenchymal Stem Cells Transplantation for Treatment of Ischemic Stroke.Chinese journal of integrative medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo explore the efficiency and safety of Sanhuang Xiexin decoction in the treatment of acute ischemic stroke (AIS) patients after endovascular intervention examination.
methodsIn this prospective observational study, 121 AIS patients admitted in our hospital were enrolled from January 2012 to December 2015. They were randomly divided into two groups, 61 patients received Sanhuang Xiexin decoction + basic treatment (SX group) and 60 patients received basic treatment (control group). The prescription of Sanhuang Xiexin decoction was taken in the SX group, with one dose (100 ml), twice a day for 7 days orally. For all patients, blood samples were drawn on the first morning and sixth morning after endovascular intervention examination under fasting state for Fib (fibrinogen), PAgT (platelet aggregation test), CRP (C-reactive protein), and TMAO (trimethylamine oxide) tested. Estimate the changes in plasma Fib, PAgT, CRP, and TMAO levels and the syndrome of fire-heat scores.
resultsThe plasma Fib, PAgT, CRP, and TMAO levels in the SX group were significantly lower than those in the control group (P
conclusionsThe prescription of Sanhuang Xiexin is efficient and safe in the treatment of AIS patients after endovascular intervention examination through reducing the inflammatory factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.